Answers are grounded in this paper and cite their sources.
On May 28, 1998, the Food and Drug Administration (FDA) Gastrointestinal Advisory Committee voted to approve infliximab (Remicade, also formerly known as cA2), a chimeric antitumor necrosis factor alpha antibody for the treatment of patients with Crohn's disease (CD). The Committee voted unanimously to approve the drug for two narrow indications: as single dose therapy for the treatment of patients with moderate-severe inflammatory disease refractory to conventional therapy and as a three-dose infusion regimen for patients with actively draining external fistulae. The unanimity of the vote belied the heated discussion that preceded the Advisory Committee's approval. The day-long meeting, held in the ballroom at the Bethesda Holiday Inn, Bethesda, Maryland, was filled to capacity. Many seats appeared to be occupied by Wall Street analysts who were easily recognizable by their frequent impromptu exits and hallway cellphone calls during any apparent shift in the momentum of the day's proceedings. The day's events unfolded much like the final day of a court trial, with closing (defense) statements being presented by infliximab's sponsor Centocor and their consultants, followed by the FDA's closing statements with some opposing viewpoints, after which the jury (the Advisory Committee) posed questions to both the sponsors and the FDA, and debated the evidence before publicly voting on the two individual indications. The morning began with patient testimonies detailing the complex, chronic, and debilitating nature of the disease on their quality of life. At least one Wall Street analyst was seen engrossed in a financial analysis titled “The Crohn's Population and Market Penetration,” as a 23-year-old woman described her experience with her penetrating, fistulizing disease. The scientific and clinical rationale for the use of infliximab in CD was presented on behalf of Centocor by Dr. Sander Van Deventer. His presentation was followed by Dr. Thomas Schaible, director of Clinical Immunology Research at Centocor, who presented data supporting the efficacy of infliximab in CD. Dr. Roger Cohen followed with an analysis of the toxicity data focusing particularly on lymphoma risk. Dr. Daniel Present then offered a personal clinical perspective on the unique value of infliximab in treating refractory fistulae. Schaible reviewed in detail the data from two openlabeled CD trials with 31 patients, and two randomized placebo controlled trials that studied 108 patients with moderate-severe inflammatory disease (the “T16” study) and 94 patients with refractory externally draining fistulae (the “T20” study). The T16 study, a multicenter, randomized, doubleblinded, placebo-controlled study randomized 108 patients to either placebo or 5, 10, or 20 mg/kg of infliximab as a single 2-hour infusion. The primary endpoint was a reduction in the Crohn's Disease Activity Index (CDAI) score by at least 70 points at week 4. Those patients who responded to the initial blinded therapy at week 8, were then rerandomized at week 12 to receive either placebo or 10 mg/kg infliximab every 8 weeks for an additional 4 doses. During the initial treatment phase the highest response rate, 81%, occurred in the 5 mg/kg dose group. Patients in the 10 and 20 mg/kg groups had a 50 and 64% response rate, respectively, compared with the 17% response rate in the placebo group. The response rate in all three treatment groups were significantly better than placebo with a p < 0.001 for the 5 mg/kg group. Furthermore, clinical remission, defined as a CDAI score of <150, was achieved by 30% of patients in the 5 mg/kg group compared with only 8% of patients in the placebo group (p = 0.004). During the retreatment phase, the median time spent with a maintained response for treated patients was 241 days—longer but not significantly different than the median time with a maintained response for patients retreated with placebo (176 days). The second indication for infliximab sought by the sponsor was for closure of refractory externally draining fistulae. Ninety percent of these fistulas were perianal while 10% were enterocutaneous fistulae draining through the abdominal wall. Ninety-four patients were randomized to either placebo or 5 mg/kg or 10 mg/kg infusion of infliximab. The primary efficacy endpoint was defined as a >50% reduction from baseline in the number of draining fistulas for at least two consecutive visits. Patients were given three infusions at weeks 0, 2, and 6, and then evaluated every 4 weeks thereafter until week 18. Sixty-two percent of patients treated with 5 mg/kg and 55% of patients treated with 10 mg/kg achieved the primary endpoint, compared with 29% of placebo patients (p = 0.02 and p = 0.07, respectively). However, according to the analysis subsequently presented by the FDA, there was no difference beyond week 18 between the treatment groups and the placebo group in maintaining closure of fistulae. Furthermore, the FDA analysis revealed that new fistulae developed during the study in nine patients treated with infliximab and occurred in some patients who had been classified as responders. The FDA also revealed that seven patients in the active treatment group developed an abscess in the area of the draining fistula; at least six of these patients had been considered responders. No recalculations had been done of the response rate after these patients were redefined as nonresponders. Safety data were extensively reviewed. Given the small number of CD patients treated with infliximab, the sponsor pooled safety data from all compiled trials of infliximab, except those which evaluated treatment for sepsis. Four hundred fifty-three patients were available for analysis. The incidence of infection (mostly minor), malignancy, and infusion reaction was higher in patients treated with infliximab than with placebo. Human antichimeric antibodies (HACAs) developed in 18 CD patients treated with infliximab and generally occurred in low titre. In addition, 12% of CD patients developed a positive antinuclear antibody and 9% of treated patients developed an antidouble stranded DNA antibody; two treated patients developed a drug-induced lupus syndrome. Four serious infusion reactions occurred in treated patients compared with none for placebo. Infusion reactions were more common upon repeat dosing and in patients who had developed HACAs. A major concern was voiced regarding the development of lymphoma in four infliximab-treated patients— three patients with rheumatoid arthritis and one with CD. Dr. Roger Cohen, a Centocor consultant, reviewed the data and concluded that a relationship between infliximab and the development of lymphoma was unlikely. However, the FDA felt that given the limited number of patients in the safety database, a relationship between infliximab and the development of lymphoma could not be excluded. After conclusion of the sponsor's and FDA's presentation, a spirited discussion ensued in which a number of issues were raised and mostly left unanswered: Is infliximab steroid sparing? How can short-term treatment rates be sustained? Are there any factors predictive of a response? Should a fistula that stops draining but which then develops an adjacent abscess be considered as “healed”? Is infliximab toxicity or efficacy enhanced or reduced in combination with other immunosuppressive therapies? Should infliximab be used solely as a bridge to a longer-acting agent (i.e., 6-MP or azathioprine) to maintain remission? Can the adult efficacy and toxicity data be extrapolated to the pediatric population? Given the unknown long-term risk and benefit of infliximab, the FDA pointedly emphasized that they fully expected that the long-term retreatment study planned by the sponsor would proceed as planned. On August 24, 1998, the FDA approved the use of infliximab for the above-described indications.
No takes yet. Share an insight, caveat, or question.
Asher Kornbluth (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: